Loading the session
Loading the session
Loading instrument
$50.96
+4.64%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:29 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 4 Nov 2026 gain of 5.0% was 4.0× its average daily move of 1.3% over the past year, and its largest one-day gain since 4 Feb 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
1 month: +9.8% (SPY −1.6%). 3 months: −0.6% (SPY −0.4%). 1 year: +9.2% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GSK, SPY · as of 4 Nov 2026
$0.4518 a share, payable 7 Jan 2027; unchanged from the previous payment (ex-date 14 Aug 2026).
Corporate actions record · as of 5 Nov 2026
The 4 Nov 2026 close of $51.15 was 3.8% above its 50-day average ($49.29) and 2.3% below its 200-day average ($52.36). It has closed below the 200-day for 52 sessions, since 24 Aug 2026. The 50-day average crossed below the 200-day on 5 Aug 2026, 64 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $51.15 on 4 Nov 2026: 17.1% below the 52-week high of $61.70 (18 Feb 2026) and 11.7% above the low of $45.81 (20 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
February 5, 2025
+8.21%June 3, 2024
−8.69%December 6, 2022
+7.85%